Since IFN-γ/TNF-α treatment of patients is not advisable, HER2+ breast cancer patients were treated with HER2-pulsed dendritic cells (DC) to restore depressed Th1 response which seems to be due to a functional and reversible cytokine shift (69). Here, ERBB2 is linked to breast carcinoma.